← Back to headlines
Ocugen Stock Drops Following Mid-Stage Trial Data for GA Therapy
Ocugen's stock has fallen after the release of 12-month data from its mid-stage trial for a geographic atrophy (GA) therapy.
24 Mar, 12:37 — 24 Mar, 12:37
Sources
Showing 1 of 1 sources
Related Stories
Northern Samar Lawmaker Seeks Review of High Power Costs in Off-Grid Areas
just now
Farmers group tells Palace: Include us in crisis committee
just now
Philippines Declares National Energy Emergency Amid Middle East Crisis, Fuel Supply Concerns
just now
Philippines Transport Faces Disruptions Amid Rising Fuel Costs
just now